An interventional study of Direct selective laser trabeculoplasty in Pseudoexfoliation Glaucoma, sponsored by Vance Thompson Vision. Not yet recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Vance Thompson Vision · Not applicable, Interventional, and Treatment
Prospective, multi-center, single arm, interventional study evaluating DSLT in patients with pseudoexfoliative glaucoma.
72 studies on the registry are indexed under Exfoliation Syndrome; 20 are open to participants now.
This study's planned enrollment of 40 is below the median of 64 across 34 interventional studies indexed under Exfoliation Syndrome.
Browse Exfoliation Syndrome studies →Vance Thompson Vision is the lead sponsor of 20 studies on the registry; 7 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with DSLT
Device: Direct selective laser trabeculoplasty
A non-invasive laser procedure for treating glaucoma and ocular hypertension by improving the eye's natural fluid drainage
Primary Effective Endpoint
Proportion of eyes achieving ≥20% reduction in washed-out IOP at month 6 compared to washed-out baseline IOP
Time frame: 6 months
Secondary Effective Endpoint
Proportion of eyes achieving ≥ 20% reduction in washed out IOP at month 12 compared to washed-out baseline IOP
Time frame: 12 months
Secondary Effective Endpoint
Mean washed out IOP reduction at 6 and 12 months as compared to washed-out baseline IOP
Time frame: 6 and 12 months
Secondary Effective Endpoint
Change in # of glaucoma medication(s) at 6 and 12 months
Time frame: 6 and 12 months
Secondary Effective Endpoint
Proportion of medication free eyes post-DSLT at 6 and 12 months
Time frame: 6 and 12 months
Secondary Effective Endpoint
Rate of secondary surgical interventions (SSIs) at 12 months
Time frame: 12 months
Secondary Effective Endpoint
Kaplan-Meier survival analysis at 12 months: time to failure (failure defined as an increase in glaucoma medications from baseline or additional IOP lowering procedure)
Time frame: 12 months
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vance Thompson Vision